Fundamental Analysis of Bone Biologics Corp. WT - Growth / Value Index
BBLGW - Valuation Highlights
Valuation Analysis
Tremendous increasing in Book Value last 3 year
Tsr Value Index - Very Poor Score of 5.00
Price to Book Ratio of 14.85 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | -8.83 | -1.62 | 99.61 % | |
Price to Book | 14.31 | 3.63 | -100.00 % | 7.21 |
Price to Sales | 0 | 0 | 0 % | |
Enterprise Value to EBITDA Multiple | 0 | -1.16 | 99.31 % |
BBLGW - Profitability Highlights
Profitability Analysis
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
Tsr Profitability Index - Very Poor Score of 5.00
Piotroski F Score - Very Poor Value of 2.0
Very Low Dividend Yield of 0 %
Negative Net profit for last two years
Company Net profit is Negative for last 5 Quarters
In the last three years, the company has given poor Net Margin
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | -162.02 | -223.83 | 99.10 % | -23.56 |
Return On Asset | -113.22 | -174.04 | 99.00 % | -22.55 |
Net Profit Margin | 0 | 0 | 0 % | 0 |
Operating Profit Margin | 0 | 0 | 0 % | 0 |
EBITDA Margin | 0 | 0 | 0 % | 0 |
Highlights
Market Cap | 0 |
Enterprise Value | 0 |
Price/Book TTM | 14.31 |
Outstanding Share | 0 |
Float/ Outstanding Share | % |
Dividend Yield | 0 % |
Share Holding
Guru Numbers
Price/Graham No | 0 |
Peter Lynch Ratio | 0 |
Piotroski F Score | 2.00 |
Altman Z Score | -35.12 |
Sloan Ratio | 0.798 |
Peter Lynch Fair Value | 0 |
BBLGW - Growth Highlights
Growth Analysis
Annual sales of the company is increased for three years in a row
Quarterly sales in last 5 years is trending up
Steady increase in Total Assets for last 3 Years
Tsr Growth Index - Poor Score of 24.43
Quarterly sales in last 5 Quarter is trending down
Annual sales in last 3 years is trending down
Operating Cash Flow decreasing for last 3 year
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | NA | % | % |
Gross Profit | NA | % | % |
EBITDA | -7574.18 K | 77.49 % | 41.70 % |
Net Profit | -6104.80 K | 338.19 % | 44.13 % |
EPS | -4.54 | 25381.42 % | NA |
BBLGW - Stability Highlights
Stability Analysis
Tsr Stability Index - Excellent Score of 91.67
Company is Debt Free
Net Debt zero balance-sheet with high liquidity
Cash ratio of 3.64
Company financial liquidity has improved
Altman Z Score of -35.12 suggest high risk
Company is unable to generate enough free cash to support the business.
Interest Coverage of 0
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0 | 0 % | 0 |
Cash Ratio | 3.64 | 23.04 % | |
Quick Ratio | 4.89 | -97.88 % | 25.32 |
Shareholders Equity | 77.76 | 11.07 % | |
Debt to EBITDA | 0 | 0 % |
Historical Valuation Ratios of Bone Biologics Corp. WT
Historical Valuation Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Profitability Ratios of Bone Biologics Corp. WT
Historical Profitability Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Efficiency Ratios of Bone Biologics Corp. WT
Historical Efficiency Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Historical Solvency Ratios of Bone Biologics Corp. WT
Historical Solvency Ratios
Loading ...
![loading](https://www.stockaio.com/static/img/LoadingMedium.gif)
Note : All Data Generated at the End of Trading Hours (EOD Data)